Výsledky vyhledávání

Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis*

Autor: Mary Palmen, Michael Safdi, Sunanda V. Kane, Dory Solomon, Seymour Katz, Mph M. Mazen Jamal Md, Ben Dolin, Karen Barrett

Publikováno v: Inflammatory Bowel Diseases. 18:1026-1033

Background: This was a phase IV, multicenter, open-label, 12–14-month study to assess clinical recurrence in patients with ulcerative colitis (UC) who received maintenance treatment with MMX Multi Matrix System (MMX) mesalamine. A secondary outcome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ce88ac5299e34115d32bdcb390a2507
https://doi.org/10.1002/ibd.21841

Zobrazit plný text záznamu

Population Pharmacokinetic Modeling of Epoetin Delta in Pediatric Patients With Chronic Kidney Disease

Autor: James A. Dowell, Mary Palmen, William Knebel, Marc R. Gastonguay

Publikováno v: The Journal of Clinical Pharmacology. 48:837-848

This analysis quantifies the population pharmacokinetics of subcutaneous and intravenous epoetin delta, an epoetin produced in a human cell line, in pediatric patients with chronic kidney disease and estimates the effects of covariate factors on epoe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179a63abd7a2e852f5280703f5af22b5
https://doi.org/10.1177/0091270008318218

Zobrazit plný text záznamu

Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer

Autor: Lorne Erdile, Kees L. M. C. Franken, Anand G. Menon, Sjoerd H. van der Burg, Peter J. K. Kuppen, Rienk Offringa, Rob A. E. M. Tollenaar, Karin A. J. de Cock, Mary Palmen, Anke Redeker, Cornelis J.H. van de Velde, Cornelis J. M. Melief, Jan W. Drijfhout

Publikováno v: European Journal of Immunology. 31:146-155

Colorectal carcinoma is commonly associated with mutation and overexpression of p53, making this antigen a potential target for immune intervention. We analyzed humoral and proliferative immunity against p53 in the blood of patients with resected pri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69cb3f9fc927ef4c7a1aecfb0409dcc7
https://doi.org/10.1002/1521-4141(200101)31:1<146::aid-immu146>3.0.co

Zobrazit plný text záznamu

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study

Autor: L. Engels, Daan W. Hommes, David Stephenson, P. Connor, Filip Baert, John Ramage, Mary Palmen, R Joseph, O. Dewit, L. A. van der Waaij, Geert D'Haens

Publikováno v: Alimentary pharmacology & therapeutics, 24(7), 1087-1097. Wiley-Blackwell

SPD476 (MMX mesalazine), is a novel, once daily, high-strength mesalazine formulation (1.2 g/tablet) that utilizes Multi Matrix System (MMX) technology to delay and extend delivery of the active drug throughout the colon. To assess the safety and eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d81e02e76294d2162ac3e1359ca79ea5
https://pubmed.ncbi.nlm.nih.gov/17597673

Zobrazit plný text záznamu

Plný text ve formátu HTML

Tu1196 Evaluation of the Pharmacokinetics and Safety of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis

Autor: Patrick Martin, Carmelo Cuffari, Mary Palmen, Bartosz Korczowski, Krzysztof Fyderek, Stuart Hossack, Heather Van Heusen, Susi Inglis, David M. Pierce

Publikováno v: Gastroenterology. 146:S-781

AIM: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum distinguished by relapsing and remitting gastrointestinal and systemic symptoms. Mesalamine (5-aminosalicylic acid; 5-ASA) has proven efficacy in the induction and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c67f99a41ad1d1d076cd39e9a9e1063
https://doi.org/10.1016/s0016-5085(14)62817-1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání